{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kwiecinska K"],"funding":["Polish National Research Centre"],"pagination":["10732748211064776"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9052811"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["29"],"pubmed_abstract":["<h4>Introduction</h4>Hematopoietic stem cell transplantation (HSCT) is the essential and often the only curative therapeutic option in high risk and relapsed pediatric acute lymphoblastic leukemia (ALL).<h4>Methods</h4>The objective of the study was to investigate whole-genome expression in children with high risk or relapsed ALL referred for HSCT. Gene expression was assessed in 18 children with ALL referred for HSCT (10 high risk, 8 relapsed; median age of 9.4 years) and in a control group of 38 obese children (median age of 14.1 years). Whole-genome expression was assessed in leukocytes using GeneChip® HumanGene 1.0 ST microarray.<h4>Results</h4>The analysis of genomic profiles revealed a significantly lower expression of 21 genes with a defined function, involved in immunoglobulin production, lymphocyte function, or regulation of DNA processing in ALL patients referred for HSCT compared with the control group.<h4>Conclusion</h4>Genome expression of patients with ALL in remission referred to HSCT revealed deep immunosuppression of both B-cell and T-cell lineages, which may increase the probability of donor cell engraftment."],"journal":["Cancer control : journal of the Moffitt Cancer Center"],"pubmed_title":["Genetic Profiling in Children With Acute Lymphoblastic Leukemia Referred for Allogeneic Hematopoietic Stem Cell Transplantation."],"pmcid":["PMC9052811"],"funding_grant_id":["NN 407 198737"],"pubmed_authors":["Piechota M","Balwierz W","Bik-Multanowski M","Michal Korostynski","Kwiecinska K","Strojny W","Szymon Skoczen"],"additional_accession":[]},"is_claimable":false,"name":"Genetic Profiling in Children With Acute Lymphoblastic Leukemia Referred for Allogeneic Hematopoietic Stem Cell Transplantation.","description":"<h4>Introduction</h4>Hematopoietic stem cell transplantation (HSCT) is the essential and often the only curative therapeutic option in high risk and relapsed pediatric acute lymphoblastic leukemia (ALL).<h4>Methods</h4>The objective of the study was to investigate whole-genome expression in children with high risk or relapsed ALL referred for HSCT. Gene expression was assessed in 18 children with ALL referred for HSCT (10 high risk, 8 relapsed; median age of 9.4 years) and in a control group of 38 obese children (median age of 14.1 years). Whole-genome expression was assessed in leukocytes using GeneChip® HumanGene 1.0 ST microarray.<h4>Results</h4>The analysis of genomic profiles revealed a significantly lower expression of 21 genes with a defined function, involved in immunoglobulin production, lymphocyte function, or regulation of DNA processing in ALL patients referred for HSCT compared with the control group.<h4>Conclusion</h4>Genome expression of patients with ALL in remission referred to HSCT revealed deep immunosuppression of both B-cell and T-cell lineages, which may increase the probability of donor cell engraftment.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan-Dec","modification":"2025-04-05T11:03:01.584Z","creation":"2025-04-05T11:03:01.584Z"},"accession":"S-EPMC9052811","cross_references":{"pubmed":["35470705"],"doi":["10.1177/10732748211064776"]}}